We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current GIFLF market cap is 7.28B. The company's latest EPS is EUR 0.0863 and P/E is 122.71.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 5.15B | 5.39B | 5B | 6.06B | 6.59B |
| Operating Income | 1.09B | 1.06B | 628.25M | 804.2M | 798.48M |
| Net Income | 625.15M | 618.55M | 182.8M | 208.28M | 59.32M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 15.54B | 15.27B | 19.23B | 21.53B | 21.44B |
| Total Liabilities | 8.7B | 8.55B | 11.09B | 13.08B | 13.47B |
| Total Equity | 6.85B | 6.72B | 8.15B | 8.46B | 7.97B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | 568.93M | 1.11B | 596.98M | -10.87M | 208.28M |
| Investing | -548.79M | -858.12M | -29.39M | -1.98B | -397.64M |
| Financing | -332.36M | -354.4M | 1.47B | -173.49M | 186.05M |
| Market Cap | 7.28B |
| Price to Earnings Ratio | 122.71 |
| Price to Sales Ratio | 1.1 |
| Price to Cash Ratio | 13.75 |
| Price to Book Ratio | 0.91 |
| Dividend Yield | - |
| Shares Outstanding | 687.55M |
| Average Volume (1 week) | 1.48k |
| Average Volume (1 Month) | 1.74k |
| 52 Week Change | -15.95% |
| 52 Week High | 15.80 |
| 52 Week Low | 7.4599 |
| Spread (Intraday) | 0.83 (7.55%) |
| Company Name | Grifols Sa (PK) |
| Address |
calle jesus i maria, 6 barcelona, catalonia 08174 |
| Website | https://www.grifols.com |
| Industry | in vitro,in vivo diagnostics (2835) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
